In re Zyprexa Products Liability Litigation
Decision Date | 01 December 2009 |
Docket Number | No. 04-MD-1596.,No. 07-CV-645.,04-MD-1596.,07-CV-645. |
Citation | 671 F.Supp.2d 397 |
Parties | In re ZYPREXA PRODUCTS LIABILITY LITIGATION. Jim Hood, Attorney General of the State of Mississippi, ex rel. The State of Mississippi, Plaintiff, v. Eli Lilly & Company, Defendant. |
Court | U.S. District Court — Eastern District of New York |
Bailey Perrin Bailey, by Leslie B. LaMacchia, Andrew Kirkendall, Elizabeth Williams, Fletcher Vines Trammell, Michael W. Perrin, Robert W. Cowan, Kenneth Camp Bailey, Houston, TX, The Quin Firm PLLC, by William M. Quin, II, Booneville, MS, W. Howard Gunn & Associates, by W. Howard Gunn, Aberdeen, MS, for plaintiff.
Pepper Hamilton LLP, by Andrew R. Rogoff, Matthew J. Hamilton, Nina M. Gussack, Allan Andrew Thoen, Samuel J. Abate, Jr., John F. Brenner, George A. Lehner, Philadelphia, PA, Watkins Ludlam Winter & Stennis, P.A., by Douglas T. Miracle, Lisa A. Reppeto, Neville H. Boschert, Jackson, MS, for Defendant.
MEMORANDUM, ORDER AND PARTIAL SUMMARY JUDGMENT
I. Introduction
Plaintiff, the State of Mississippi, moves for partial summary judgment on its claims for compensation for its payments for the drug Zyprexa. Defendant Eli Lilly & Company ("Lilly") moves for summary judgment of dismissal. For the reasons set forth below, Lilly's motion for summary judgment is granted in part and reserved in part. Mississippi's motion for partial summary judgment is denied.
Mississippi's action is one of many thousands of cases relating to Lilly's drug Zyprexa, one of a number of "atypical" or "second-generation" antipsychotic drugs to come on the market over the past twenty years. Second-generation antipsychotics were perceived of as more effective than predecessor drugs for treating serious psychiatric disorders, such as schizophrenia and bipolar disorder. They have been widely prescribed for these and a variety of other mental conditions. Zyprexa has been used by large numbers of people, resulting in tens of billions of dollars in total sales for Lilly.
Zyprexa is widely believed to be one of the most efficacious of the second-generation antipsychotics. See Benedict Carey, Study Finds Little Advantage in New Schizophrenia Drugs, N.Y. Times, Sept. 20, 2005, at F1 () . As the court has previously observed: In re Zyprexa Prods. Liab. Litig., 493 F.Supp.2d 571, 575 (E.D.N.Y. 2007); see also In re Zyprexa Prods. Liab. Litig., 253 F.R.D. 69, 77 (E.D.N.Y. 2008).
In the case of some users who were leading dismal, hazardous lives as a result of their mental problems, Zyprexa has enabled a greatly improved quality of life. Large numbers of such patients have been litigants in this court. See, e.g., Belcher v. Eli Lilly & Co., No. 06-CV-2782, 2009 WL 3597447 at *9 (E.D.N.Y. Oct. 16, 2009) ( ; Folse v. Eli Lilly & Co., No. 04-CV-1612, 2009 WL 3596526 at *9 (E.D.N.Y. Oct. 16, 2009) ( ...
To continue reading
Request your trial-
In re Chinese Manufactured Drywall Prods. Liab. Litig.
...941 (D.Ariz. 2011); Hinds Cty., Miss. v. Wachovia Bank, N.A., 708 F.Supp.2d 348, 366 n.11 (S.D.N.Y. 2010); In re Zyprexa Prods. Liab. Litig., 671 F.Supp.2d 397, 430 (E.D.N.Y. 2009); In re Conagra Peanut Butter Prods. Liab. Litg., 2009 WL 799422, at *1 (N.D. Ga. 2009); 15 Charles Alan Wright......
-
Trisvan v. Heyman, 16–CV–00084 (MKB)
...sub nom. In re Wellbutrin XL Antitrust Litig. , No. 15-2875, 2017 WL 3529114 (3d Cir. Aug. 9, 2017) ; In re Zyprexa Prod. Liab. Litig. , 671 F.Supp.2d 397, 412 (E.D.N.Y. 2009). The Court notes that categorization of Defendants as either brand-name or generic manufacturers impacts whether th......
-
In re Chinese Manufactured Drywall Prods. Liab. Litig.
...941 (D.Ariz.2011); Hinds Cty., Miss. v. Wachovia Bank, N.A., 708 F.Supp.2d 348, 366 n. 11 (S.D.N.Y.2010); In re Zyprexa Prods. Liab. Litig., 671 F.Supp.2d 397, 430 (E.D.N.Y.2009); In re Conagra Peanut Butter Prods. Liab. Litg., 2009 WL 799422, at *1 (N.D.Ga.2009); 15 Charles Alan Wright, Ar......
-
Compound Prop. Mgmt. v. Build Realty, Inc.
...or wire fraud. But Bridge directly abrogated McLaughlin's understanding of the RICO statute. See In re Zyprexa Prods. Liab. Litig., 671 F.Supp.2d 397, 444 (E.D.N.Y. 2009) (“McLaughlin has been partially abrogated by the Supreme Court's subsequent decision in Bridge v. Phoenix Bond & Indem. ......
-
CHAPTER § 10.02 Third-Party Payors: Who They Are and What They Do
...of $73,200,000 even though the state failed to prove it had suffered any actual damages) with In reZyprexa Prods. Liab. Litig., 671 F. Supp.2d 397, 458-59 (E.D.N.Y. 2009) (rejecting State of Mississippi's claim to recover penalties for alleged mass violations of its Medicaid-fraud act becau......